Kate Rochlin, Ph.D., Chief Operating Officer

April 9 | 10:15am | Salone dei Cavalieri, Section 2

New York, NY


IN8bio is a clinical-stage biopharmaceutical company focused on developing novel gamma-delta T cell therapies for solid and hematological tumors. The company’s lead, INB-400, is in a Phase 2 clinical trial in which autologous gamma-delta T cells, which are engineered to be chemotherapy resistant, will be assessed in newly diagnosed glioblastoma. The Company has two Phase 1 clinical trials: INB-200, for the treatment of patients with newly diagnosed GBM, and INB-100, for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation. INB-100 is the first allogeneic gamma-delta T cell therapy to show in-vivo persistance and expansion for 365 days and 100% of evaluable treated patients remain in remission, with 6 past the one-year mark. In addition, the company’s DeltEx platform has yielded a broad portfolio of preclinical programs, including INB-300 and INB-500, addressing other solid and hematological tumor types through non-signaling CAR-T’s and iPSCs.

By using this website you agree to accept our Privacy Policy and Terms & Conditions